Last reviewed · How we verify

DDAVP — Competitive Intelligence Brief

DDAVP (DDAVP) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin receptor agonist. Area: Endocrinology, Hematology.

marketed Vasopressin receptor agonist V2 vasopressin receptor (AVPR2) Endocrinology, Hematology Small molecule Live · refreshed every 30 min

Target snapshot

DDAVP (DDAVP) — Chang, Steve S., M.D.. DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) receptor agonist to increase water reabsorption in the kidneys and promote von Willebrand factor release from endothelial cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DDAVP TARGET DDAVP Chang, Steve S., M.D. marketed Vasopressin receptor agonist V2 vasopressin receptor (AVPR2)
TERLIPRESSIN TERLIPRESSIN marketed Vasopressin Receptor Agonist [EPC] 2022-01-01
Vasopressin administration Vasopressin administration Assistance Publique Hopitaux De Marseille phase 3 Vasopressin receptor agonist V1A and V2 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin receptor agonist class)

  1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
  2. Chang, Steve S., M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DDAVP — Competitive Intelligence Brief. https://druglandscape.com/ci/ddavp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: